Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of rozanolixizumab in ocular myasthenia gravis
CTR20262520Phase 3Active
- Sponsor
- UCB
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of rozanolixizumab in myasthenia gravis (MG), sponsored by UCB. Started Jul 2026; status: active.
02
Drugs
rozanolixizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on CTR20262520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262520.